Primary Biliary Cholangitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major primary biliary cholangitis markets reached a value of US$ 510 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,200 Million by 2034, exhibiting a growth rate (CAGR) of 8.06% during 2024-2034.
The primary biliary cholangitis market has been comprehensively analyzed in IMARC's new report titled "Primary Biliary Cholangitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Primary biliary cholangitis is a chronic autoimmune illness that primarily affects the tiny bile ducts located in the liver. As a result, bile builds up in the liver, leading to hepatic cell damage over time. Many individuals suffering from this condition may have little to no symptoms as well. The most common indications of the illness include lethargy, fatigue, itching, dry eyes and mouth, an enlarged liver or spleen, yellowing of the skin and eyes, abdominal pain, weak and brittle bones, diarrhea, swollen legs, ankles and feet, weight loss, fat deposits, hyperpigmentation, etc. Diagnosing primary biliary cholangitis typically requires a combination of thorough clinical assessment, medical history evaluation, as well as a complete blood workup and physical examination. The healthcare practitioner may also perform several other imaging studies, such as abdominal ultrasound and magnetic resonance imaging, to visualize the liver and bile ducts, assess their structure, and identify any abnormalities. In some cases, a liver biopsy is further utilized to confirm the diagnosis and determine the degree of liver damage among patients.
The rising cases of immune-mediated disorders, in which the body's defense system targets the cells that line the intrahepatic bile ducts, resulting in inflammation, are primarily driving the primary biliary cholangitis market. Additionally, the increasing prevalence of various risk factors, including genetic predisposition, hormonal changes, exposure to infectious agents or toxins, regular smoking, etc., is further propelling the market growth. Moreover, the widespread adoption of effective drugs, such as ursodeoxycholic acid and obeticholic acid, to help in reducing liver inflammation and improving bile flow within the body is acting as another significant growth-inducing factor. In line with this, the rising usage of immunosuppressive medications, like corticosteroids and azathioprine, for treating the condition is also augmenting the market growth. These therapeutic agents work by modulating the immune response to minimize hepatic damage, preserve liver function, and alleviate the symptoms of the ailment. Furthermore, the escalating demand for endoscopic retrograde cholangiopancreatography-guided implantation of a biliary endoprosthesis, owing to its numerous benefits, including relief of bile duct obstruction and improved quality of life for patients, is expected to drive the primary biliary cholangitis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the primary biliary cholangitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for primary biliary cholangitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the primary biliary cholangitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the primary biliary cholangitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the primary biliary cholangitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current primary biliary cholangitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Late-Stage Pipeline Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the primary biliary cholangitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the primary biliary cholangitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the primary biliary cholangitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of primary biliary cholangitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of primary biliary cholangitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of primary biliary cholangitis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with primary biliary cholangitis across the seven major markets?
What is the size of the primary biliary cholangitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of primary biliary cholangitis?
What will be the growth rate of patients across the seven major markets?
Primary Biliary Cholangitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for primary biliary cholangitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the primary biliary cholangitis market?
What are the key regulatory events related to the primary biliary cholangitis market?
What is the structure of clinical trial landscape by status related to the primary biliary cholangitis market?
What is the structure of clinical trial landscape by phase related to the primary biliary cholangitis market?
What is the structure of clinical trial landscape by route of administration related to the primary biliary cholangitis market?
The primary biliary cholangitis market has been comprehensively analyzed in IMARC's new report titled "Primary Biliary Cholangitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Primary biliary cholangitis is a chronic autoimmune illness that primarily affects the tiny bile ducts located in the liver. As a result, bile builds up in the liver, leading to hepatic cell damage over time. Many individuals suffering from this condition may have little to no symptoms as well. The most common indications of the illness include lethargy, fatigue, itching, dry eyes and mouth, an enlarged liver or spleen, yellowing of the skin and eyes, abdominal pain, weak and brittle bones, diarrhea, swollen legs, ankles and feet, weight loss, fat deposits, hyperpigmentation, etc. Diagnosing primary biliary cholangitis typically requires a combination of thorough clinical assessment, medical history evaluation, as well as a complete blood workup and physical examination. The healthcare practitioner may also perform several other imaging studies, such as abdominal ultrasound and magnetic resonance imaging, to visualize the liver and bile ducts, assess their structure, and identify any abnormalities. In some cases, a liver biopsy is further utilized to confirm the diagnosis and determine the degree of liver damage among patients.
The rising cases of immune-mediated disorders, in which the body's defense system targets the cells that line the intrahepatic bile ducts, resulting in inflammation, are primarily driving the primary biliary cholangitis market. Additionally, the increasing prevalence of various risk factors, including genetic predisposition, hormonal changes, exposure to infectious agents or toxins, regular smoking, etc., is further propelling the market growth. Moreover, the widespread adoption of effective drugs, such as ursodeoxycholic acid and obeticholic acid, to help in reducing liver inflammation and improving bile flow within the body is acting as another significant growth-inducing factor. In line with this, the rising usage of immunosuppressive medications, like corticosteroids and azathioprine, for treating the condition is also augmenting the market growth. These therapeutic agents work by modulating the immune response to minimize hepatic damage, preserve liver function, and alleviate the symptoms of the ailment. Furthermore, the escalating demand for endoscopic retrograde cholangiopancreatography-guided implantation of a biliary endoprosthesis, owing to its numerous benefits, including relief of bile duct obstruction and improved quality of life for patients, is expected to drive the primary biliary cholangitis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the primary biliary cholangitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for primary biliary cholangitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the primary biliary cholangitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the primary biliary cholangitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the primary biliary cholangitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current primary biliary cholangitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Late-Stage Pipeline Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the primary biliary cholangitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the primary biliary cholangitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the primary biliary cholangitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of primary biliary cholangitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of primary biliary cholangitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of primary biliary cholangitis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with primary biliary cholangitis across the seven major markets?
What is the size of the primary biliary cholangitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of primary biliary cholangitis?
What will be the growth rate of patients across the seven major markets?
Primary Biliary Cholangitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for primary biliary cholangitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the primary biliary cholangitis market?
What are the key regulatory events related to the primary biliary cholangitis market?
What is the structure of clinical trial landscape by status related to the primary biliary cholangitis market?
What is the structure of clinical trial landscape by phase related to the primary biliary cholangitis market?
What is the structure of clinical trial landscape by route of administration related to the primary biliary cholangitis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PRIMARY BILIARY CHOLANGITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PRIMARY BILIARY CHOLANGITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PRIMARY BILIARY CHOLANGITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 PRIMARY BILIARY CHOLANGITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PRIMARY BILIARY CHOLANGITIS - UNMET NEEDS
10 PRIMARY BILIARY CHOLANGITIS - KEY ENDPOINTS OF TREATMENT
11 PRIMARY BILIARY CHOLANGITIS - MARKETED PRODUCTS
11.1 List of Primary Biliary Cholangitis Marketed Drugs Across the Top 7 Markets
11.1.1 Urso (Ursodeoxycholic acid) - Alfa Farmaceutici/sanofi-aventis
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Ocaliva (Obeticholic acid) - Intercept Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 PRIMARY BILIARY CHOLANGITIS - PIPELINE DRUGS
12.1 List of Primary Biliary Cholangitis Pipeline Drugs Across the Top 7 Markets
12.1.1 CNP-104 - Cour Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Seladelpar - CymaBay Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Elafibranor - Genfit
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 OP 724 - Ohara Pharmaceutical
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Golexanolone - Umecrine Cognition
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. PRIMARY BILIARY CHOLANGITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PRIMARY BILIARY CHOLANGITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PRIMARY BILIARY CHOLANGITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Primary Biliary Cholangitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Primary Biliary Cholangitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Primary Biliary Cholangitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Primary Biliary Cholangitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Primary Biliary Cholangitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Primary Biliary Cholangitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Primary Biliary Cholangitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Primary Biliary Cholangitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Primary Biliary Cholangitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Primary Biliary Cholangitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Primary Biliary Cholangitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Primary Biliary Cholangitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Primary Biliary Cholangitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Primary Biliary Cholangitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Primary Biliary Cholangitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Primary Biliary Cholangitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Primary Biliary Cholangitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Primary Biliary Cholangitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Primary Biliary Cholangitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Primary Biliary Cholangitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Primary Biliary Cholangitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Primary Biliary Cholangitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Primary Biliary Cholangitis - Access and Reimbursement Overview
16 PRIMARY BILIARY CHOLANGITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PRIMARY BILIARY CHOLANGITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PRIMARY BILIARY CHOLANGITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PRIMARY BILIARY CHOLANGITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PRIMARY BILIARY CHOLANGITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PRIMARY BILIARY CHOLANGITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 PRIMARY BILIARY CHOLANGITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PRIMARY BILIARY CHOLANGITIS - UNMET NEEDS
10 PRIMARY BILIARY CHOLANGITIS - KEY ENDPOINTS OF TREATMENT
11 PRIMARY BILIARY CHOLANGITIS - MARKETED PRODUCTS
11.1 List of Primary Biliary Cholangitis Marketed Drugs Across the Top 7 Markets
11.1.1 Urso (Ursodeoxycholic acid) - Alfa Farmaceutici/sanofi-aventis
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Ocaliva (Obeticholic acid) - Intercept Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 PRIMARY BILIARY CHOLANGITIS - PIPELINE DRUGS
12.1 List of Primary Biliary Cholangitis Pipeline Drugs Across the Top 7 Markets
12.1.1 CNP-104 - Cour Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Seladelpar - CymaBay Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Elafibranor - Genfit
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 OP 724 - Ohara Pharmaceutical
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Golexanolone - Umecrine Cognition
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. PRIMARY BILIARY CHOLANGITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PRIMARY BILIARY CHOLANGITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PRIMARY BILIARY CHOLANGITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Primary Biliary Cholangitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Primary Biliary Cholangitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Primary Biliary Cholangitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Primary Biliary Cholangitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Primary Biliary Cholangitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Primary Biliary Cholangitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Primary Biliary Cholangitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Primary Biliary Cholangitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Primary Biliary Cholangitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Primary Biliary Cholangitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Primary Biliary Cholangitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Primary Biliary Cholangitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Primary Biliary Cholangitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Primary Biliary Cholangitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Primary Biliary Cholangitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Primary Biliary Cholangitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Primary Biliary Cholangitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Primary Biliary Cholangitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Primary Biliary Cholangitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Primary Biliary Cholangitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Primary Biliary Cholangitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Primary Biliary Cholangitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Primary Biliary Cholangitis - Access and Reimbursement Overview
16 PRIMARY BILIARY CHOLANGITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PRIMARY BILIARY CHOLANGITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PRIMARY BILIARY CHOLANGITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
